Crestwood Advisors Group LLC Sells 1,000 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Crestwood Advisors Group LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.0% during the first quarter, Holdings Channel.com reports. The firm owned 100,730 shares of the biopharmaceutical company’s stock after selling 1,000 shares during the quarter. Crestwood Advisors Group LLC’s holdings in Ultragenyx Pharmaceutical were worth $3,647,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of RARE. GAMMA Investing LLC grew its position in shares of Ultragenyx Pharmaceutical by 76.2% during the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 323 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth about $35,000. GF Fund Management CO. LTD. purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth about $82,000. Quarry LP purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth about $84,000. Finally, denkapparat Operations GmbH purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter worth about $207,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock opened at $26.39 on Tuesday. The company has a market capitalization of $2.49 billion, a P/E ratio of -4.49 and a beta of 0.26. The company’s fifty day moving average is $35.65 and its two-hundred day moving average is $38.20. Ultragenyx Pharmaceutical Inc. has a 1 year low of $25.81 and a 1 year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to analysts’ expectations of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The firm’s revenue was up 28.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.03) EPS. As a group, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analysts Set New Price Targets

RARE has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price target for the company. Morgan Stanley decreased their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, July 14th. Wedbush decreased their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research note on Monday, July 14th. Finally, Wells Fargo & Company decreased their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating for the company in a research note on Thursday, July 10th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and an average target price of $83.64.

Insider Buying and Selling

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company’s stock, valued at $573,712.16. This trade represents a 13.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.